High-dose daptomycin for treatment of complicated gram-positive infections: A large, multicenter, retrospective study

Pharmacotherapy

Volumn 31, Issue 6, 2011, Pages 527-536

  Kullar, Ravina ^a   Davis, Susan L ^a   Levine, Donald P ^b   Zhao, Jing J ^c   Crank, Christopher W ^d   Segreti, John ^d   Sakoulas, George ^e   Cosgrove, Sara E ^f,g   Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e SHARP MEMORIAL HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g Division of Infectious Diseases   (United States)

Author keywords

Clinical response; Gram positive infections; High dose daptomycin; Safety

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; CREATINE KINASE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; BONE INFECTION; CASE STUDY; CATHETER INFECTION; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; FEMALE; GRAM POSITIVE INFECTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; INFECTIOUS ARTHRITIS; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; OSTEOMYELITIS; OUTCOME ASSESSMENT; PROSTHESIS INFECTION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SKIN INFECTION; THROMBOCYTOSIS; TREATMENT DURATION; UNITED STATES; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; WOUND INFECTION;

AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 79957597382     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.6.527     Document Type: Article

References (40)

1. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY antimicrobial surveillance program (1997-2002). Diagn Microbiol Infect Dis 2004;50:59-69.
2. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163-70. (Pubitemid 46856806)
3. National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
4. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:1079-81. (Pubitemid 351590040)
5. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
6. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47:1598-603. (Pubitemid 36548543)
7. Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007;51:1787-94.
8. Cubist Pharmaceuticals, Inc. Cubicin (daptomycin for injection) product information. Lexington, MA; 2003.
9. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81. (Pubitemid 38781657)
10. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
11. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001;45:454-9.
12. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007;60:334-40.
13. Rose WE, Leonard SN, Sakoulas G, et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52:831-6.
14. Chambers HF, Basuino L, Diep BA, et al. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob Agents Chemother 2009;53:1463-7.
15. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short-duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008;62:1455-64.
16. Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin outcomes registry and experience (CORE). Int J Antimicrob Agents 2009;33:543-8.
17. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-80.
18. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (≥ 8 mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-19.
19. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633-8.
20. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-79.
21. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically; approved standard, 8th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
22. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986-2007). J Clin Microbiol 2008;46:2950-4.
23. Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001;39:2439-44. (Pubitemid 32606216)
24. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007;45:329-32.
25. Peacock SJ, Moore CE, Justice A, et al. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun 2002;70:4987-96.
26. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005;43:5026-33. (Pubitemid 41483999)
27. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32.
28. Miller BA, Gray A, Leblanc TW, Sexton DJ, Martin AR, Slama TG. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis 2010;50:e63-8.
29. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006;50:1581-5.
30. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40:1058-60.
31. Cunha BA, Krol V, Kodali V. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 2008;37:72-5.
32. Cunha BA, Mickail N, Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007;36:456-61.
33. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005;49:2735-45.
34. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52:3061-7.
35. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004;24:41-57.
36. Canepari P, Boaretti M, Lleo MM, Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 1990;34:1220-6. (Pubitemid 20177384)
37. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948-53.
38. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology 2008;81:79-91. (Pubitemid 351182681)
39. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-9. (Pubitemid 44527494)
40. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50:1568-74.